13F Holdings
中文EN

DWTX Dogwood Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1818844 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY34.1%
TTM EPS YoY140.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-70.5%
ROA-30.0%
ROIC (approx.)-78.2%
Asset turnover—

Leverage & solvency

Liabilities / assets15.2%
Debt / equity0.00x
Current ratio2.78x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.65x
Accruals ratio-10.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—————
R&D expense$21.87M$3.53M$1.73M$8.07M$10.80M
SG&A expense$6.10M$8.70M$3.72M$4.25M$4.85M
Operating income-$27.97M-$12.23M-$5.45M-$12.32M-$15.64M
Pretax income-$34.04M-$12.35M-$5.30M-$12.25M-$15.96M
Income tax$221,096-$503———
Net income-$34.26M-$12.35M-$5.30M-$12.25M-$15.96M
EBITDA-$27.97M-$12.22M———
EPS (basic)-7.13-12.52-7.05-1.11-1.92
EPS (diluted)-7.13-12.52-7.05-1.11-1.92
Weighted avg. shares (diluted)4.98M1.03M751,07111.07M8.33M
Banking
Net interest income——$150,904$67,475$5,672
Balance sheet
Cash & equivalents$6.52M$14.85M$3.32M$7.03M$14.01M
Current assets$8.43M$16.54M$4.17M$8.37M$15.78M
PP&E, net$12,754$16,811———
Goodwill$12.40M$11.81M———
Intangibles$68.99M$65.71M———
Total assets$90.17M$94.31M$4.17M$8.37M$15.78M
Current liabilities$3.06M$3.18M$358,548$1.04M$1.28M
Total liabilities$15.27M$30.03M$358,548$1.04M$1.28M
Shareholders' equity$74.90M-$10.12M$3.81M$7.33M$14.50M
Shares outstanding29.74M1.33M770,31718.33M8.33M
Cash flow statement
Operating cash flow-$15.62M-$8.79M-$4.87M-$11.47M-$15.69M
Investing cash flow—$3.76M———
Financing cash flow$7.28M$16.70M$1.16M$4.49M-$97,604
Depreciation & amortization$2,063$12,177———
Stock-based compensation$355,642$476,021$619,972$582,659$322,881

Free plan shows the latest 5 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.